Autoimmune Diseases and Risk of Non-Hodgkin Lymphoma: A Mendelian Randomisation Study

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-11-06 DOI:10.1002/cam4.70327

Xiaoting Shi, Joshua D. Wallach, Xiaomei Ma, Tormod Rogne

{"title":"Autoimmune Diseases and Risk of Non-Hodgkin Lymphoma: A Mendelian Randomisation Study","authors":"Xiaoting Shi, Joshua D. Wallach, Xiaomei Ma, Tormod Rogne","doi":"10.1002/cam4.70327","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Non-Hodgkin lymphoma (NHL) is one of the most common haematologic malignancies in the world. Despite substantial efforts to identify causes and risk factors for NHL, its aetiology is largely unclear. Autoimmune diseases have long been considered potential risk factors for NHL. We carried out Mendelian randomisation (MR) analyses to examine whether genetically predicted susceptibility to ten autoimmune diseases (Behçet's disease, coeliac disease, dermatitis herpetiformis, lupus, psoriasis, rheumatoid arthritis, sarcoidosis, Sjögren's syndrome, systemic sclerosis, and type 1 diabetes) is associated with risk of NHL.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Two-sample MR was performed using publicly available summary statistics from cohorts of European ancestry. For NHL and four NHL subtypes, we used data from UK Biobank, Kaiser Permanente cohorts, and FinnGen studies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Negative associations between type 1 diabetes and sarcoidosis and the risk of NHL were observed (odds ratio [OR] 0.95, 95% confidence interval [CI]: 0.92–0.98, <i>p</i> = 5 × 10<sup>−3</sup>, and OR 0.92, 95% CI: 0.85–0.99, <i>p</i> = 2.8 × 10<sup>−2</sup>, respectively). These findings were supported by the sensitivity analyses accounting for potential pleiotropy and weak instrument bias. No significant associations were found between the other eight autoimmune diseases and NHL risk.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings suggest that genetically predicted susceptibility to type 1 diabetes, and to some extent sarcoidosis, might reduce the risk of NHL. However, future studies with different datasets, approaches, and populations are warranted to further examine the potential associations between these autoimmune diseases and the risk of NHL.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 21","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70327","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Non-Hodgkin lymphoma (NHL) is one of the most common haematologic malignancies in the world. Despite substantial efforts to identify causes and risk factors for NHL, its aetiology is largely unclear. Autoimmune diseases have long been considered potential risk factors for NHL. We carried out Mendelian randomisation (MR) analyses to examine whether genetically predicted susceptibility to ten autoimmune diseases (Behçet's disease, coeliac disease, dermatitis herpetiformis, lupus, psoriasis, rheumatoid arthritis, sarcoidosis, Sjögren's syndrome, systemic sclerosis, and type 1 diabetes) is associated with risk of NHL.

Methods

Two-sample MR was performed using publicly available summary statistics from cohorts of European ancestry. For NHL and four NHL subtypes, we used data from UK Biobank, Kaiser Permanente cohorts, and FinnGen studies.

Results

Negative associations between type 1 diabetes and sarcoidosis and the risk of NHL were observed (odds ratio [OR] 0.95, 95% confidence interval [CI]: 0.92–0.98, p = 5 × 10⁻³, and OR 0.92, 95% CI: 0.85–0.99, p = 2.8 × 10⁻², respectively). These findings were supported by the sensitivity analyses accounting for potential pleiotropy and weak instrument bias. No significant associations were found between the other eight autoimmune diseases and NHL risk.

Conclusion

These findings suggest that genetically predicted susceptibility to type 1 diabetes, and to some extent sarcoidosis, might reduce the risk of NHL. However, future studies with different datasets, approaches, and populations are warranted to further examine the potential associations between these autoimmune diseases and the risk of NHL.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

自身免疫性疾病与非霍奇金淋巴瘤风险：孟德尔随机研究

背景：非霍奇金淋巴瘤（NHL）是世界上最常见的血液恶性肿瘤之一。尽管为确定NHL的病因和风险因素做出了大量努力，但其病因在很大程度上仍不清楚。长期以来，自身免疫性疾病一直被认为是 NHL 的潜在风险因素。我们进行了孟德尔随机化（MR）分析，以研究基因预测的十种自身免疫性疾病（白塞氏病、乳糜泻、疱疹性皮炎、狼疮、银屑病、类风湿性关节炎、肉样瘤病、斯约格伦综合征、系统性硬化症和 1 型糖尿病）的易感性是否与 NHL 的风险有关：使用欧洲血统队列中可公开获得的汇总统计数据进行了双样本 MR 分析。对于 NHL 和四种 NHL 亚型，我们使用了来自英国生物库、Kaiser Permanente 队列和 FinnGen 研究的数据：结果：1 型糖尿病和肉样瘤病与 NHL 风险呈负相关（几率比 [OR] 0.95，95% 置信区间 [CI]：0.92-0.98，P＜0.05）：0.95，95%置信区间[CI]：0.92-0.98，p = 5 × 10-3；OR 0.92，95%置信区间：0.85-0.99，p = 2.8 × 10-2）。考虑到潜在的多效性和微弱的工具偏差进行的敏感性分析也支持这些结果。其他八种自身免疫性疾病与 NHL 风险之间没有发现明显的关联：这些研究结果表明，从基因上预测的1型糖尿病易感性，以及在一定程度上预测的肉样瘤病，可能会降低NHL风险。然而，未来的研究需要采用不同的数据集、方法和人群，以进一步研究这些自身免疫性疾病与 NHL 风险之间的潜在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.